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The management of diabetes without any side eﬀects remains a challenge in medicine. In this study, antidiabetic activity and the
mechanismofactionofscorpioncombinedwithgypsum (SG)were investigated. Streptozotocin-induced diabetic micewere orally
administrated with scorpion(200mgkg−1 per day) in combinationwith gypsum (200mgkg−1 per day) for 5 weeks. SG treatment
resultedindecreasedbody weight,bloodglucoseandlipidlevels,andincreasedserumandpancreaticinsulinlevelsindiabetic mice.
Furthermore, SGsigniﬁcantlyincreased thenumber andvolumeof beta cells inthe IsletsofLangerhansandpromotedperoxisome
proliferator-activated receptor gamma and pancreatic duodenal homeobox 1 expressions in pancreatic tissues. However, scorpion
or gypsum alone had no signiﬁcant eﬀect in this animal model. Metformin showed a slight or moderate eﬀect in this diabetic
model, but this eﬀect was weak compared with that of SG. Taken together, SG showed a new antidiabetic eﬀect in streptozotocin-
induced diabetic mice. This eﬀect may possibly be involved in enhancing beta-cell regeneration and promoting insulin secretion
by targeting PPARγ and PDX-1. Moreover, this new eﬀect of SG oﬀers a promising step toward the treatment of diabetic patients
with beta-cell failure as a complementary and alternative medicine.
1.Introduction
In the coming years, the number of people with diabetes
in the world will more than double, from 171 million in
2000 to 366 million in 2030 [1]. In 2007, >110 million
individuals in Asia were living with diabetes [2]. Diabetes
mellitus is associated with the development of micro- and
macrovascular complications, which are the major causes of
morbidity and death. Treatment of diabetes mellitus usually
involves diet control, exercise and the use of hypoglycemic
diets and drugs. However, many oral medicines have a
number of adverse eﬀects [3]. The management of diabetes
without any side eﬀects continues to remain a challenge to
the medical system. Type 1 diabetic and terminal type 2
diabetic patients still depend largely on insulin treatment.
However, insulin has limitations in terms of treatment, such
as hypoglycemia, allergic reaction, insulin intolerance and
inconveniences related to injection. Beta-islet dysfunction
might be a key to the development of diabetes mellitus [4].
No special antidiabetic drugs have yet to show that the activ-
ities of promoting β-islet regeneration, though peroxisome
proliferator-activated receptorgamma (PPARγ) agonists and
incretin-mimetic agents have the most promising action in
the protection of beta cells [5].
The application of Chinese medicines for antidiabetic
activities have been recently reviewed [6–9]. Most of these
drugs are derived from herb extracts or herbal formulas, and
are widely used by patients with diabetes mellitus. Most have
been found to have a positive eﬀect on hyperglycemia and
diabetic complications. The use of Chinese herbal medicines2 Evidence-Based Complementary and Alternative Medicine
in diabetes is promising, although its eﬀectiveness has yet to
be fully proven [10]. However, there are clinical limitations
to the application of Chinese medicines in diabetic patients
because of inappropriate use (or combination use) or the
lack of scientiﬁc and systematic evidence. In addition, most
therapeutic plans still focus on lowering blood glucose levels
or the number of diabetic complications. Indeed, protection
or regeneration of beta cells should be considered the key
strategies to the treatment of diabetes mellitus.
Scorpion or gypsum in combination with other Chinese
medicines is mainly used to treat diabetic neuropathy [11]
or ameliorate the syndrome of thirst [12]. At present,
however, there have been no systematic and scientiﬁc trials
conducted to study their antidiabetic activities. To the
authors’ knowledge, neither scorpion nor gypsum alone has
signiﬁcant hypoglycemiceﬀects. In thisstudy, a combination
of two Chinese medicines, scorpion and gypsum (SG),
appeared to have potential antidiabetic properties mediated
by promoting the regeneration of beta islet cells.
2.Methods
2.1. Preparation of Extracts. Scorpion (Buthus martensii
kirsch, Quanxie, Batch No. 20090314) and gypsum (Shigao,
Batch No. 20090118) were obtained from the Shenzhen
Leepheng Medicine Co., Ltd. To lower the toxic eﬀect, we
discarded the toxic sting in the tail of the scorpion before
its whole body was used for further preparations. First, the
scorpion was dried overnight at 60◦C and then reduced to a
powder. Gypsum was added to distilled water (1g:5ml) and
cooked at ∼95◦C for 1h. Aqueous extracts of gypsum were
ﬁltered through a cotton gauze. The residual precipitates of
gypsum were discarded (∼90%). The powdered scorpion
was combined with the aqueous extract of gypsum (200mg
scorpionand 200mggypsumin 1ml),slowly cooledat room
temperature and stored at 4◦C until further use. Extracts
of scorpion or gypsum alone were also prepared. Gypsum
solution was substituted with water for the scorpion extract;
no scorpion powder was added to the gypsum solution.
2.2. Animals and Diets. Male NIH mice (SPF grade, Cer-
tiﬁed No. SCXK(Guangdong) 2003-0002) were obtained
from the Guangdong Medical Laboratory Animal Center
(Guangzhou, Guangdong, China). Animals were kept in
an environmentally controlled breeding room (temperature:
20 ± 2◦C, humidity: 60 ± 5%, 12-h dark/light cycle). They
were fed standard laboratory chow with water ad libitum
and were fasted from 9:00a.m. to 3:00p.m. before the
experiments. The research was conductedin accordance with
the Declaration of Helsinki and the Guide for the Care and
Use of Laboratory Animals as adopted and promulgated
by the United States National Institutes of Health and
approved by the Animal ethics Committee of Tsinghua
U n i v e r s i t y ,C h i n a .N o r m a lc h o wd i e t sw e r eo b t a i n e df r o m
the Guangdong Medical Laboratory Animal Center. These
contained crude protein (20%), crude fat (4%) and crude
carbohydrates (60%) (gg−1).
2.3. Preparation of Diabetic Mouse Model. Male NIH mice
weighing 18–20g were selected for this study. First, the
animals were subjected to fasting for 24h but were given
free access to water. Diabetes was subsequently induced in
the animals through intraperitoneal (ip) administration of
streptozotocin (STZ, Sigma, USA) at a dose of 100mgkg−1
body weight. STZ was freshly prepared in an ice-cold citrate
buﬀer (0.1mmoll−1, pH 4.5) and immediately injected into
the animals (within 5min). A week later, high and steady
blood glucose levels were observed in STZ-induced mice. At
this point, the STZ-induced mice with high blood glucose
levels (>12mmoll−1) were selected as diabetic models.
2.4. Experimental Procedure. Normal mice were randomly
divided into two subgroups (n = 10): normal control
mice and normal mice treated with the scorpion extracts
(350mgkg−1 per day) combined with gypsum (350mgkg−1
per day). STZ-treated diabetic mice were randomly divided
into ﬁve subgroups(n = 10):Group 1, diabetic control mice;
Group 2, diabetic mice treated with scorpion (350mgkg−1
per day) combined with gypsum (350mgkg−1 per day);
Group 3, diabetic mice treated with scorpion (350mgkg−1
per day); Group 4, diabetic mice treated with gypsum
(350mgkg−1 per day) and Group 5, diabetic mice treated
with metformin (250mgkg−1 per day). The tested samples
were administered orally. Normal and diabetic controls
received distilled water with similar volume (0.1ml/10g
body weight). The administration of extracts was continued
for 5 weeks, once daily. In a separate trial, after 5 weeks
of treatment, the treatment was terminated for 1 week
to determine whether the blood glucose level increased in
mice. Blood samples were collected from tail veins at 6h
after the administration of extracts for biochemical assaying.
The anesthetized mice (ip injection of pentobarbital at a
dose of 35mgkg−1) were sacriﬁced by cervical dislocation
after their blood was collected. Serum was separated for
biochemicalassays. Pancreatic tissuewasremovedandfrozen
immediately in liquid nitrogen for biochemical analysis.
Fresh pancreatic tissue was ﬁxed in 10% formalin solution
for 48h for histopathological examination.
2.5. Histopathology. Pancreatic tissue was processed for
routine paraﬃn-wax histology and sections were stained
with hematoxylin and eosin (H&E). Five non-overlapping
adjacent sections were observed for the Islets of Langerhans
to measure the diameter from each group sample.
2.6. Oral Glucose Tolerance Test. Oral glucose-tolerance test
was conducted as prescribed previously with a slight modiﬁ-
cation [13]. In a separate trial, four groups of animals were
adopted (n = 6): normal, diabetic control mice, diabetic
mice treated with scorpion (350mgkg−1 per day) combined
withgypsum(350mgkg−1 perday)anddiabeticmicetreated
with metformin (250mgkg−1 p e rd a y ) .T h em i c ew e r e
fasted for 6h following 5 weeks of treatment. Using a light
anesthesia through an ip injection of pentobarbital at a dose
of35mgkg−1,bloodsampleswerecollectedfromthetailvein
of the mice for assaying blood glucose levels at 0, 0.5, 1 andEvidence-Based Complementary and Alternative Medicine 3
2h after glucose (2.5gkg−1) administration. Blood glucose
levels were determined using a commercial kit (BioSino Bio-
technology and Science Inc, Beijing, China). The curve of
blood glucose concentration and time was plotted. Area
undercircle(AUC)ofbloodglucoseandtimewerecalculated
according to the formula: AUC0−2h = [(G0h + G0.5h) ×
0.5h + (G0.5h + G1h) × 0.5h + (G1h + G2h) × 1h]/2;“G”,
blood glucose value.
2.7. Intraperitoneal Insulin-Tolerance Test. Insulin sensitivity
was assayed through ip insulin-tolerance test according to
the previous method, but with a slight modiﬁcation [14].
Four groups of animals were adopted in a separate trial
(n = 6): normal, diabetic control mice, diabetic mice treated
with scorpion(350mgkg−1 perday) combined with gypsum
(350mgkg−1 per day) and diabetic mice treated with met-
formin (250mgkg−1 p e rd a y ) .A f t e r5w e e k so ft r e a t m e n t ,
t h em i c ew e r ef a s t e df o r6 ha n da n e s t h e t i z e dw i t ha ni p
injection of pentobarbital at a dose of 35mgkg−1,a n dt h e n
received an ip injection of short-eﬀect human insulin (Novo
Nordisk,NorthCarolina,USA)atadoseof0.2Ukg−1.Blood
was collected from the tail vein for blood glucose assaying
after 0, 0.5 and 1h of insulin treatment. The decrease in the
percentage of blood glucose concentration (versus baseline
(0h)) was calculated. All values were multiplied by (−1) and
a statistical analysis was conducted.
2.8. Biochemical Analysis. Blood glucose and triglycerides,
total cholesterol, low-density lipoprotein cholesterol (LDL-
c) and high-density lipoprotein cholesterol (HDL-c) (n =
10) levels were estimated using commercial kits [BioSino
Bio-technology and Science Inc, Beijing, China [15–19]].
Serum and pancreatic insulin levels were determined using
the ABC-ELISA kit (Shanghai Westang Bio-tech, China).
2.9. Western Blotting. Freshly prepared whole pancreatic
tissues (n = 5) were homogenated and lysed with NETN
buﬀer (20mM Tris-HCl, pH 7.8, 1mM EDTA, 50mM
sodium chloride and 0.5% NP-40). Lysates were centrifuged
at 12000rpm at 4◦C for 2–10min. Supernatants were
collected, and protein concentration was determined using
the BCA assay kit (Nanjing Jiancheng Biotech, China).
Western blotting analysis was carried out according to
the manufacturer’s protocol. Antibodies against PPARγ
(Wuhan Boster Bio-Tech, China), pancreatic duodenal ho-
meobox 1 (PDX-1, Shanghai Ruicong Bio-tech, China)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Biolegend; 1:500–1000) were used. Protein expression was
visualizedwithhorseradish peroxidase-conjugatedsecondar-
y antibodies (Amersham Biosciences, USA; 1:2000) and
enhanced chemiluminescence (KPL, USA).
2.10.Data Analysis. Datawere expressed asmean ±standard
deviation (SD). Statistical analysis was performed using
one-way analysis of variance (ANOVA). The Newman-
Keuls comparisons were used to determine the source of
signiﬁcant diﬀerenceswhereappropriate.P-values<.05were
considered statistically signiﬁcant.
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Figure 1: Changes in fasting blood glucose levels with time (0–6
weeks) in mice. To be speciﬁc, the tested samples were continually
given for 5 weeks and then cancelled for 1 week. N, Normal
control mice; N + SG, normal mice treated with the aqueous
extracts of scorpion (350mgkg−1 per day) combined with gypsum
(350mgkg−1 per day); D, diabetic control mice; D + SG, diabetic
mice treated with scorpion (350mgkg−1 per day) combined with
gypsum (350mgkg−1 per day); D + G, diabetic mice treated with
gypsum (350mgkg−1 per day); D + S, diabetic mice treated with
scorpion (350mgkg−1 per day); D + M, diabetic mice treated with
metformin (250mgkg−1 per day). Data were expressed as mean ±
SD (n = 10). aaP<. 01 “D” versus “N”; bP<. 05 “D + SG” versus
“D”; cP<. 05 “D + M” versus “D”.
3.Results
3.1.BloodGlucoseLevels. STZ-induceddiabeticmiceshowed
a signiﬁcant increase in blood glucose levels compared with
normal controls during the period (Figure 1). However, this
increase was signiﬁcantly inhibited by SG during the 5-
weekperiodofadministration. Neitherscorpionnorgypsum
alone had signiﬁcant antidiabetic eﬀects, which suggested
that SG might have a synergic anti-hyperglycemic eﬀect.
However, SG had no hypoglycemic eﬀect in normal mice.
Metformin showed a signiﬁcant hypoglycemic eﬀect only at
the ﬁfth week, which suggested that metformin might be
inappropriate for the treatment of severe hyperglycemia, or
that its eﬀects might surface in a slow manner. Furthermore,
the treatment was stopped for 1 week after 5 weeks of
treatment todetermineifbloodglucoselevelswouldincrease
in diabetic mice. Interestingly, SG still had a hypoglycemic
eﬀect in diabetic mice. However, blood glucose levels in
metformin-treated mice showed a rapid rebound. Therefore,
we hypothesized that SG had a fundamental eﬀect in this
diabetic model, which was associated with a protective eﬀect4 Evidence-Based Complementary and Alternative Medicine
Table 1: Changes in fasting serum lipid levels in mice after 5 weeks of treatment.
Triglycerides (mmoll−1) Total cholesterol (mmoll−1)L D L - C ( m m o l l −1) HDL-C (mmoll−1) Total cholesterol/HDL-C
0 week 5 weeks 0 week 5 weeks 5 weeks 5 weeks 5 weeks
N1 . 0 5 ± 0.09 0.89 ± 0.22 4.14 ± 0.64 3.90 ± 0.57 1.73 ± 0.68 1.28 ± 0.18 3.10 ± 0.61
N + SG 1.03 ± 0.17 1.02 ± 0.27 4.10 ± 0.34 3.82 ± 0.67 1.69 ± 0.53 1.29 ± 0.19 2.97 ± 0.57
D0 . 9 2 ± 0.12∗ 1.25 ± 0.21∗∗ 3.67 ± 0.41 4.72 ± 1.74 1.91 ± 0.48 0.92 ± 0.21∗∗ 5.21 ± 1.62∗∗
D + SG 0.99 ± 0.11 0.90 ± 0.21∗∗ 3.52 ± 0.14 3.18 ± 0.51∗ 1.67 ± 0.21 1.03 ± 0.22 3.32 ± 0.88∗∗
D+G 1 . 0 9± 0.15∗∗ 1.38 ± 0.54 3.47 ± 1.12 3.82 ± 0.74 1.91 ± 0.33 1.08 ± 0.27 3.68 ± 1.00∗
D+S 1 . 0 6± 0.07∗∗ 1.19 ± 0.23 3.89 ± 0.37 3.89 ± 0.54 2.04 ± 0.34 1.05 ± 0.20 3.79 ± 0.71∗
D+M 0 . 9 4± 0.09 1.54 ± 0.49 3.54 ± 0.98 3.89 ± 0.57 2.31 ± 0.40 1.08 ± 0.21 3.68 ± 0.63∗
N: Normal control mice; N + SG: normal mice treated with the aqueous extracts of scorpion (350mgkg−1 per day) combined with gypsum (350mgkg−1
per day); D: diabetic control mice; D + SG: diabetic mice treated with scorpion (350mgkg−1 per day) combined with gypsum (350mgkg−1 per day);
D + G: diabetic mice treated with gypsum (350mgkg−1 per day); D + S: diabetic mice treated with scorpion (350mgkg−1 per day); D + M: diabetic mice
treated with metformin (250mgkg−1 per day). Data were expressed as mean ± SD (n = 10). ∗P<. 05, ∗∗P<. 01 “D” versus “N”; ∗P<. 05, ∗∗P<. 01 “D +
SG” versus “D”; ∗P<. 05, ∗∗P<. 01 “D + G” versus “D”; ∗P<. 05, ∗∗P<. 01 “D + S” versus “D”; ∗P<. 05 “D + M” versus “D”.
on beta-islet cells and resulted in the normalization of blood
glucose level.
3.2. Serum Lipid Levels. Diabetic mice showed a signiﬁcant
increase in serum triglyceride and decrease in HDL-C
compared with normal controls after 5 weeks of treatment
(Table 1). Serum total cholesterol and LDL-C showed an
increasing trend but had no signiﬁcant changes as com-
pared with those in normal controls. Despite this, total
cholesterol/HDL-C ratios were signiﬁcantly increased in
diabetic mice compared with those in normal controls. After
5 weeks of treatment, SG normalized diabetic dyslipidemia
in STZ-induced mice to the full extent but had no eﬀect
in normal mice. This eﬀect might be a secondary response
to antidiabetic eﬀects. Metformin appeared to have no
signiﬁcant eﬀect on lipid regulation in this diabetic model.
3.3. Body Weight, Water and Diet Intake. Diabetic mice had
signiﬁcantly decreased body weight despite an increase in
both water and diet intakes (Table 2). These symptoms are
similar to type 1 diabetic patients. SG signiﬁcantly inhibited
the decrease of body weight and resisted the increase in
both water and diet intakes in diabetic mice. Scorpion
alone eﬀected a signiﬁcant increase in the body weights of
diabetic mice buthad no signiﬁcant eﬀect on both water and
diet intakes. Gypsum alone, on the other hand, eﬀected a
signiﬁcant decrease in water intake but had no signiﬁcant
eﬀect on body-weight gain and diet intake. Metformin
eﬀected a signiﬁcant increase in body weight and a decrease
of water intake but had no eﬀect on diet intake. These results
further supported the supposition that SG had signiﬁcant
antidiabetic eﬀects.
3.4. Serum and Pancreatic Tissue Insulin Levels. There was a
signiﬁcant decrease of serum and pancreatic tissue insulin
levels in diabetic mice compared with those in normal
controls (Figure 2). This decrease was signiﬁcantly inhibited
in diabetic mice treated with SG or metformin, respectively.
Moreover, scorpion or gypsum alone had the eﬀect of
a moderate increase in serum insulin levels but had no
signiﬁcant eﬀect on pancreatic insulin levels. These results
indicated that SG might promote insulin synthesis and
release. Metformin appeared to possess the same potential
but was weaker than SG.
3.5. Histopathology. Histopathological images of H&E-
stained pancreatic tissues showed that the number and vol-
ume of Islets of Langerhans cells were signiﬁcantly reduced
in diabetic mice (Figure 3). The reduction was signiﬁcantly
inhibited in diabetic mice after SG administration. Scorpion
orgypsumalonehadnosigniﬁcanteﬀectontheregeneration
of pancreatic beta cells. Metformin also had a slight protec-
tive eﬀect on pancreatic beta cells. However, SG displayed
a higher increase in both number and volume of beta cells
in the Islets of Langerhans in diabetic mice than metformin.
These results suggested that SG might exert a hypoglycemic
eﬀect by promoting the regeneration of pancreatic beta cells.
3.6. Oral Glucose Tolerance Test. In a separate trial, diabetic
mice dosed with oral glucose load showed a signiﬁcant
increase in blood glucose level and areas under the circle
of blood glucose and time (AUC) compared with normal
controls (Figure 4). SG signiﬁcantly inhibited the increase
of blood glucose level at 1 and 2h. Metformin signiﬁcantly
inhibited this increase at 2h after oral glucose load. The
increase in AUC was signiﬁcantly inhibited in diabetic mice
after administration of SG or metformin. These results
suggested that SG can ameliorate glucose intolerance in
diabetes mellitus.
3.7. Intraperitoneal Insulin Tolerance Test. In another sepa-
rate trial, diabeticmiceshowed lessdecreaseofbloodglucose
percentage compared with normal controls after ip injection
of small dose of exogenous insulin (Figure 5). However, SG
had signiﬁcantly lowered the blood glucose level compared
with diabetic controls. Metformin had no signiﬁcant eﬀect
in diabetic mice. These results indicated that SG enhanced
insulin sensitivity and might serve as an adjunct to insulin
treatment.Evidence-Based Complementary and Alternative Medicine 5
Table 2: Changes in body weights, water and dietary intake in mice after 5 weeks of treatment.
Body weight (g) Water intake (mlg−1 body weight) Diet intake (gg−1 body weight)
Before treatment After treatment
N 32.1 ± 1.3 40.7 ± 2.4 0.24 ± 0.07 0.178 ± 0.048
D 27.4 ± 4.6∗ 29.2 ± 3.9∗∗ 0.72 ± 0.12∗∗ 0.365 ± 0.015∗∗
D + SG 26.9 ± 5.6 34.4 ± 2.3∗ 0.35 ± 0.09∗∗ 0.305 ± 0.016∗∗
D + G 26.3 ± 2.2 30.8 ± 6.5 0.45 ± 0.08∗ 0.359 ± 0.020
D + S 27.1 ± 4.1 34.7 ± 3.4∗ 0.66 ± 0.10 0.342 ± 0.053
D + M 26.7 ± 3.3 34.9 ± 4.2∗ 0.40 ± 0.07∗∗ 0.345 ± 0.022
N: Normal control mice; D: diabetic control mice; D + SG: diabetic mice treated with scorpion (350mgkg−1 per day) combined with gypsum (350mgkg−1
per day);D + G: diabeticmice treated with gypsum (350mgkg−1 per day); D + S: diabetic mice treated with scorpion (350mgkg−1 per day); D + M: diabetic
mice treated with metformin (250mgkg−1 per day). Data were expressed as mean ± SD (n = 10). ∗P<. 05, ∗∗P<. 01 “D” versus “N”; ∗P<. 05, ∗∗P<. 01
“D + SG” versus “D”; ∗P<. 05 “D + G” versus “D”; ∗P<. 05 “D + S” versus “D”; ∗P<. 05, ∗∗P<. 01 “D + M” versus “D”.
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Figure 2: Serum and pancreatic tissue insulin levels detected by ELISA after 5 weeks of treatment (a and b). N, Normal control mice;
D, diabetic control mice; D + SG, diabetic mice treated with scorpion (350mgkg−1 per day) combined with gypsum (350mgkg−1 per
day); D + G, diabetic mice treated with gypsum (350mgkg−1 per day); D + S, diabetic mice treated with scorpion (350mgkg−1 per day);
D + M, diabetic mice treated with metformin (250mgkg−1 per day). Data were expressed as mean ± SD (n = 5). aaP<. 01 “D” versus “N”;
bP<. 05, bbP<. 01 “D + SG” versus “D”; ddP<. 01 “D + G” versus “D”; eP<. 05 “D + S” versus “D”.
3.8. Western Blotting. A western blotting assay was also
conducted in pancreatic tissues because PPARγ and PDX-
1 play an important role in the development of pancreatic
b e t ac e l l s .I nt h i st r i a l ,P P A R γ and PDX-1 expressions were
signiﬁcantly decreased in diabetic mice (Figure 6). However,
SG or metformin signiﬁcantly increased the PPARγ and
PDX-1 expressions. These results suggested that SG might
promote the regeneration of pancreatic beta cells mediated
by the mechanisms of enhancing the PPARγ and PDX-1
expressions.
4.Discussion
Scorpion and gypsum have been utilized for thousands
of years as ingredients in Chinese traditional medicines.
Scorpions are mainly prescribed as an anticonvulsive, pain-
relieving, anticoagulant, anticancer and immune-regulating
medication in Chinese traditional medicine [20, 21]. On the
other hand, gypsum is mainly prescribed as a heat-clearing,
ﬁre-purging and thirst-quenching drug [22]. Gypsum in
combination with other agents has also been used to treat
diabetes [23]. There have also been claims which indicated
that scorpion combined with other Chinese medicines is
eﬀective in the treatment of type 2 DM patients [24].
However, these formulas consisted of more than ﬁve herbs,
making the research results diﬃcult to replicate due to poor
quality control. In addition, no systematic and scientiﬁc
pharmacological and mechanism assays were conducted
in animal or clinical studies. To the authors’ knowledge,
scorpion or gypsum alone has no signiﬁcant eﬀect on hyper-
glycemia in diabetic animals or humans. In earlier studies,6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Images of H&E staining (×100 magniﬁcation) in pancreatic tissues of mice (a), pancreatic islet numbers (b), and maximum
diameter of the Islets of Langerhans (c) (n = 5). Arrows indicate the Islets of Langerhans. N, Normal control mice; D, diabetic control mice;
D + SG, diabetic mice treated with scorpion (350mgkg−1 per day) combined with gypsum (350mgkg−1 per day); D + G, diabetic mice
treated with gypsum (350mgkg−1 per day); D + S, diabetic mice treated with scorpion (350mgkg−1 per day); D + M, diabetic mice treated
withmetformin(250mgkg−1 per day). Data were expressed asmean ± SD (n = 5). aaP<. 01“D” versus “N”; bbP<. 01 “D + SG” versus “D”;
cP<. 05, ccP<. 01 “D + M” versus “D”.
scorpion venom showed stimulation of glucagon secretion
andinhibitionof insulinrelease [25,26].Interestingly, inthis
study, we found that SG had antidiabetic eﬀects, and further
disclosed the action mechanisms which demonstrate the
promotionofbetaisletregenerationinSTZ-induceddiabetic
mice. In addition to hypoglycemic activities, SG had an
accompanying regulation eﬀect on dyslipidemia in diabetic
mice. SG signiﬁcantly decreased total cholesterol/HDL ratio,
which meant that this combination might have a beneﬁcial
eﬀect in reducing the risk of cardiovascular diseases in dia-
betic individuals [27]. It also ameliorated impaired insulin
sensitivity in diabetic mice. SG might also have a beneﬁcial
eﬀect in type 2 diabetic individuals because these patients
commonly display insulin resistance.
Beta cells in the Islets of Langerhans are the main organs
for synthesizing and secreting insulin [28]. In this study,
STZ irreversibly caused damage and loss in pancreatic beta
cells. However, sulfonylureas exert a hypoglycemic eﬀect
by promoting insulin secretion in pancreatic beta cells
[29]. In our preliminary trial, sulfonylureas had no eﬀect
in this animal model due to the irreversible damage in
the beta islets induced by STZ (data not shown). Thus,
metformin was selected as a positive control because its
action mechanism was involved in a non-insulin-dependent
manner. SG signiﬁcantly increased both number and volume
of pancreatic beta cells in pancreatic tissues, which might
explain why SG increased serum and pancreatic tissue
insulin levels. Furthermore, SG signiﬁcantly increased the
expressions of both PPARγ and PDX-1. PPARγ activation
restores beta-cell function in diabetic mice through the
reduction of endoplasmic reticulum stress and maintenance
of euchromatin structure [30]. PPARγ has a regulation
eﬀect on PDX-1 transcription [31]. PDX-1 governs the
early embryonic development of the pancreas and the laterEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Changes in blood glucose levels with time (a) and areas under the circle (AUC) of blood glucose and time (b) after oral glucose
load (2.5gkg−1). N, Normal control mice; D, diabetic control mice; D + SG, diabetic mice treated with scorpion (350mgkg−1 per day)
combined with gypsum (350mgkg−1 per day); D + M, diabetic mice treated with metformin (250mgkg−1 per day). Data were expressed as
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Figure 5: Changes in blood glucose levels with time (a) and decreased percentages of blood glucose level (b) after ip injection of insulin. N,
Normal control mice; D, diabetic control mice; D + SG, diabetic mice treated with scorpion (350mgkg−1 per day) combined with gypsum
(350mgkg−1 per day); D + M, diabetic mice treated with metformin (250mgkg−1 per day). Data were expressed as mean ± SD (n = 6).
aaP<. 01 “D” versus “N”; bP<. 05, “D + SG” versus “D”; cP<. 05 “D + M” versus “D”.
diﬀerentiation of insulin-producing islet beta cells of the
endocrine compartment [32, 33]. These results indicated
that SG might exert a hypoglycemic eﬀect by enhancing the
PPARγ and PDX-1 expressions and promoting regeneration
or proliferation of pancreatic β-islets.
However, whether or not constituents of boiled scorpion
could produce an antidiabetic eﬀect when combined with
a much diluted solution of calcium sulfate is still not known.
From the observedresults, a possible mechanism ofaction of
SGisdepictedinFigure 7. Webelievethatthe tiny amount of
scorpion venom which might be contained in the scorpion’s
body still showed potent pharmacological eﬀect despite our
removal ofthe toxicsting inthe end ofthe tail containing the
scorpionvenom.Gypsummight reverse theuntoward eﬀects8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: PPARγ and PDX-1 expressions in pancreatic tissues
of mice after 5 weeks of treatment. N, Normal control mice; D,
diabetic control mice; D + SG, diabetic mice treated with scorpion
(350mgkg−1 per day) combined with gypsum (350mgkg−1 per
day); D + M, diabetic mice treated with metformin (250mgkg−1
per day). Data were expressed as mean ± SD (n = 5). aaP<. 01 “D”
versus “N”; bbP<. 05, “D + SG” versus “D”; ccP<. 01 “D + M”
versus “D”.
or enhance the pharmacological eﬀect of scorpion venom.
Charybdotoxin, one of the scorpion toxins, blocks calcium-
activated potassium channels [34]. Blockade of calcium-
activated potassium channels enhances insulin secretion,
whereas blockade of Ca2+ channels suppresses insulin secre-
tion [35]. Gypsum is mainly comprised of calcium (>90%).
Itis reasonable tosuppose that the calciumin gypsumwould
activate Ca2+ channels and the charybdotoxin contained in
the scorpion would inhibit K+ channels in pancreatic beta-
islets. This dual action might have an increased eﬀect by
degrees on insulin secretion. It is also possible that Ca2+ in
gypsummightincrease thebioavailabilityofactiveprinciples
in scorpion. The active scorpion components might be able
to promote the regeneration of pancreatic beta cells. These
suppositions might explain why scorpion combined with
gypsumhas a stronger eﬀe c tt h a ns c o r p i o no rgyp s u ma l o n e .
However, they should be further validated in a future study.
In addition, metformin exerted a hypoglycemic eﬀect
in diabetic patients with slight or moderate hyperglycemia,
but failed in severe cases. Thus, in this study, we could
Scorpion +G y p s u m
Venom or other active components Venom +C a 2+
Ca2+ Ca2+
PPARγ ↑ PDX-1 ↑
Islet regeneration ↑
Antidiabetic activity
Insulin secretion ↑
K+-channels Ca+-channels
Figure 7: Hypothetical mechanism of action of SG in diabetic
animals.
not observe metformin as having signiﬁcant hypoglycemic
eﬀects in the early stages of type 1 diabetic mice induced
by STZ. Metformin exerts a hypoglycemic eﬀect through the
mechanism of activating AMPK [36]. In this research, we
found that metformin had slight protective eﬀect in pancre-
atic beta cells and that it directly promotes its regeneration
in STZ-induced diabetic mice by targeting PDX-1. To date,
PPAR-gamma agonists and incretin-mimetic agents seem to
have this potential [5]. In this study, the eﬀect of metformin
on protecting pancreatic beta cells might be consistent with
previous research [37].
5.Conclusion
SG has an antidiabetic eﬀect in STZ-induced diabetic mice
which might be involved in enhancing islet regeneration and
promoting insulin secretion. However, the exact nature of
molecular mechanisms of SG needs further investigation.
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